comparemela.com

Latest Breaking News On - Snehal patel - Page 2 : comparemela.com

Snehal Patel Buys 3,000 Shares of Greenwich LifeSciences, Inc (NASDAQ:GLSI) Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI – Get Free Report) CEO Snehal Patel acquired 3,000 shares of the company’s stock in a transaction dated Monday, April 1st. The stock was acquired at an average cost of $19.08 per share, with a total value of $57,240.00. Following the purchase, the chief executive officer now owns 5,350,777 shares of […]

Insider Buying: Greenwich LifeSciences, Inc (NASDAQ:GLSI) CEO Purchases 3,000 Shares of Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI – Get Free Report) CEO Snehal Patel purchased 3,000 shares of the stock in a transaction dated Monday, April 1st. The stock was acquired at an average cost of $19.08 per share, for a total transaction of $57,240.00. Following the completion of the transaction, the chief executive officer now owns 5,350,777 […]

Insider Buying: Greenwich LifeSciences, Inc (NASDAQ:GLSI) CEO Purchases 2,500 Shares of Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI – Get Free Report) CEO Snehal Patel bought 2,500 shares of the firm’s stock in a transaction on Friday, March 22nd. The shares were purchased at an average price of $19.98 per share, for a total transaction of $49,950.00. Following the purchase, the chief executive officer now owns 5,347,777 shares in […]

Greenwich LifeSciences, Inc (NASDAQ:GLSI) CEO Acquires $49,950 00 in Stock

Greenwich LifeSciences, Inc (NASDAQ:GLSI) CEO Acquires $49,950 00 in Stock
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Greenwich LifeSciences Partners with GEICAM in Spain & Conducts First Site Initiation Visits in Europe

STAFFORD, Texas, March 12, 2024 (GLOBE NEWSWIRE) Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the initiation of the first clinical sites in Europe in collaboration with GEICAM in Spain. The Company has partnered with GEICAM, the largest academic breast cancer research network in Spa

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.